Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -41.39% | -246.44% | -110.70% | 10.09% | -111.00% |
| Total Depreciation and Amortization | 46.15% | 90.00% | 70.00% | 50.00% | 44.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 129.71% | 209.24% | 84.13% | 87.58% | 72.72% |
| Change in Net Operating Assets | -96.44% | 294.71% | 497.82% | -105.58% | 7,205.45% |
| Cash from Operations | -81.63% | -64.51% | -72.14% | -69.49% | -55.32% |
| Capital Expenditure | -- | 100.00% | -- | -- | -916.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -- | -- | 604,916.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,022.22% | -99.97% | 29,983.33% | -- | 12.50% |
| Repurchase of Common Stock | -80.00% | -200.00% | 28.57% | 70.00% | 6.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -47,400.00% | -- | -- |
| Cash from Financing | 103.19% | -99.98% | 66,350.00% | 703,590.00% | -28,925.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -179.34% | -379.83% | -56.48% | 1,113.93% | 453.42% |